What should you expect in your first week on semaglutide?

What typically happens on the first injection day

Most people expect a dramatic first day on semaglutide and are quietly surprised when nothing much happens. That anticlimactic experience is not a bad sign. The 0.25 mg starting dose is a titration dose, designed to help the body begin adjusting rather than to produce immediate appetite suppression or weight loss. Semaglutide has a half-life of roughly one week, so plasma levels build gradually over four to five weeks before reaching a meaningful steady state.

Some people notice a faint queasiness a few hours after the injection, particularly if they eat a large meal close to the injection time. Others feel a subtle quieting of the constant mental pull toward food, sometimes called food noise. Still others feel nothing at all through day one. Every one of these responses falls within the normal range for a first dose.

What day one is not: a reliable indicator of whether the medication will work. Semaglutide's effect on appetite grows progressively over weeks, not hours. Week one is about laying the groundwork, not seeing results. That framing helps most people get through the early period without unnecessary worry in either direction.

Why the dose starts so low and escalates slowly

The dose escalation schedule for Wegovy (semaglutide 2.4 mg), the FDA-approved formulation for chronic weight management, follows a five-step plan with approximately four weeks at each level: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, arriving at the 2.4 mg maintenance dose around week 17. Providers may pause escalation if side effects are poorly tolerated at any step.

This slow approach is grounded in clinical data. A pooled analysis of the STEP 1, 2, and 3 trials found that gastrointestinal adverse events were reported far more frequently during the dose-escalation period, with the cumulative incidence of a first GI event plateauing after approximately week 20. Most of the nausea that people experience on semaglutide clusters in the first few months of titration, not throughout the entire course of treatment. These findings are from clinical trials of Wegovy (semaglutide 2.4 mg), an FDA-approved medication. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials.

Because the first week sits at the lowest dose in the entire schedule, it is often the gentlest week. If side effects return or feel worse when the dose steps up at week five, that is a common and expected pattern. It does not mean something has gone wrong. The body adapts again between each dose increase.

When appetite changes and food noise first appear

Semaglutide reduces hunger through two overlapping pathways. Centrally, it activates GLP-1 receptors in the hypothalamus and brainstem that regulate satiety signals. Research published in Neuropharmacology found that semaglutide also reduces appetite while increasing dopamine reward signaling in the brain, which helps explain the reduction in food cravings and the quieting of intrusive thoughts about eating. Peripherally, semaglutide slows gastric emptying, so food stays in the stomach longer and the sense of fullness persists for more time after meals. A 2021 study in Diabetes, Obesity and Metabolism confirmed that semaglutide significantly reduced energy intake and decreased preference for fatty, energy-dense foods.

How quickly these changes become noticeable varies considerably. Some people describe noticing smaller portions feel satisfying within the first two or three days. Others do not notice any clear change in hunger for two to four weeks. Both timelines fall within the normal range. At 0.25 mg, the lowest dose in the schedule, consistent appetite suppression is often subtle. It typically becomes stronger and more reliable with each step up in dose.

If week one feels no different from any other week from a hunger standpoint, that is not cause for concern. The effect accumulates, and the most meaningful appetite-suppression effects for most people arrive later in the titration phase.

The most common side effects in week one

Gastrointestinal symptoms are the most frequently reported side effects when starting semaglutide. A pooled analysis of the STEP 1, 2, and 3 clinical trials of semaglutide 2.4 mg (the Wegovy formulation) found the following rates compared to placebo:

Source: pooled STEP 1-3 gastrointestinal tolerability analysis, published in Diabetes, Obesity and Metabolism. These figures come from clinical trials of Wegovy (semaglutide 2.4 mg), an FDA-approved medication for chronic weight management in adults. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials; individual experiences with any formulation will vary.

Of the GI adverse events recorded in that analysis, 99.5% were non-serious and 98.1% were mild to moderate in severity. Only 4.3% of participants permanently discontinued treatment due to GI side effects across those three trials. Beyond GI symptoms, some people also report headache, fatigue, and mild dizziness in the first week, particularly if food intake drops sharply without adequate fluid replacement.

Nausea: timing and typical duration

Nausea is the single most reported first-week complaint, and understanding the typical timeline helps set realistic expectations. Symptoms commonly appear within 24 to 48 hours of the injection, peak around days three to seven, and in most cases begin improving before the next weekly dose is due.

The pooled STEP 1-3 analysis found that the median duration of nausea episodes was 8 days. The median for diarrhea was 3 days and for vomiting 2 days. Constipation lasted a median of 47 days, which makes it the GI side effect that requires the most sustained management through hydration, dietary fiber, and regular movement. These figures are from clinical trials of Wegovy (semaglutide 2.4 mg), an FDA-approved medication. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials.

Nausea tends to return briefly with each dose increase and then settle again as the body adapts at the new level. People who felt comfortable at 0.25 mg may experience a short return of queasiness when moving to 0.5 mg at week five. That recurrence is part of the normal titration pattern. In most cases it is milder than the initial onset and resolves faster, because the body has already learned how to adapt.

If nausea during week one is significantly affecting the ability to eat or drink, adjustments to meal timing, portion size, and food choices can make a real difference.

What to eat and avoid to reduce nausea

Semaglutide slows gastric emptying, meaning food moves from the stomach to the small intestine more slowly than before. Large, fatty, or heavily spiced meals that were comfortable to eat previously can sit heavily in a slower-emptying stomach and amplify nausea. A few practical adjustments help most people through the first week.

• Eat smaller meals more often. Five or six smaller meals spread through the day are far better tolerated than two or three large ones. Stop eating at the first signal of fullness, even if the plate is not empty.
• Avoid high-fat and greasy foods. Fried foods, rich sauces, and fatty cuts of meat linger in a slower stomach and are a reliable nausea trigger. Bland lower-fat options such as eggs, rice, oatmeal, toast, and cooked vegetables are generally well tolerated.
• Eat slowly and chew thoroughly. Rushing a meal on semaglutide can cause the stomach to send distress signals before the brain has caught up to a fullness cue.
• Stay upright after eating. Waiting at least 30 minutes before lying down aids motility and reduces acid reflux, which often accompanies slowed gastric emptying.
• Try ginger. Ginger has been studied as a natural remedy for nausea and is widely used for motion sickness and pregnancy-related nausea. Ginger tea, ginger chews, or ginger supplements may help reduce mild to moderate nausea for some people. Speak with your prescribing provider before adding any supplement, as appropriate options depend on individual health history and any other medications being taken.

For a thorough guide to meal structure, protein targets, and which foods support both GI comfort and weight loss outcomes on semaglutide, see What should you eat while taking semaglutide? Protein intake is especially relevant from the start: protecting lean muscle during calorie reduction matters for long-term outcomes, as covered in How do you prevent muscle loss on a GLP-1?

Why hydration matters more than usual in week one

Dehydration is a specific risk during the early weeks on semaglutide, for two reasons that compound each other. First, GLP-1 receptors in the brain affect thirst signaling, so the body may not send clear cues that fluids are needed even when they are running low. Second, nausea, vomiting, and diarrhea in the early weeks all cause measurable fluid loss.

The FDA has added warnings to GLP-1 receptor agonist prescribing labels regarding acute kidney injury resulting from dehydration caused by GI side effects, including cases that required dialysis. Staying ahead of fluid loss in the first week reduces this risk substantially and is one of the simplest protective steps available.

A practical daily target: at least 64 oz (about 8 cups) of water, spread through the day in small sips rather than large amounts at once. Drinking a large quantity of fluid at a single meal can worsen feelings of fullness and nausea. If vomiting or significant diarrhea occurs, replacing electrolytes alongside water is important to avoid an imbalance.

Warning signs of dehydration worth watching for include dark-colored urine, infrequent urination, dizziness when standing, and dry mouth that does not resolve with small sips. If any of these appear alongside persistent vomiting, contact the prescribing provider before the next dose.

The injection itself: an educational overview

The following is an educational overview only. For specific technique, dosing instructions, and storage, refer to the Instructions for Use that accompany the medication from the dispensing pharmacy and follow the guidance of the prescribing provider. Educational content is not a substitute for those instructions or for medical training.

Semaglutide is administered subcutaneously, meaning just under the skin rather than into muscle, once per week. The abdomen, front thigh, and back of the upper arm are the three standard injection areas. The injection itself is generally described as mild. For technique steps, site rotation, warming instructions, and storage, follow the Instructions for Use provided by the dispensing pharmacy and the guidance of the prescribing provider. If the injection site becomes unusually red, swollen, warm, or tender in the days following a dose, report that to the prescribing provider.

Normal first-week adjustments versus symptoms that need a provider

Not every first-week symptom requires medical contact, but a few do. The table below summarizes what is typically a normal part of adjustment versus what warrants calling a provider or seeking urgent care.

Always follow the specific guidance of the prescribing provider regarding when to call. Individual health history affects which thresholds apply, and no general table substitutes for that personalized guidance.

Week one in the broader picture

Week one is rarely the chapter where the medication's effects become visible. That is an important piece of framing to hold on to. The STEP 1 trial of semaglutide 2.4 mg (Wegovy) found that statistically significant weight differences compared to placebo were detectable at four weeks, and maximum effect was seen around weeks 60 to 68. These are outcomes from the Wegovy clinical trial. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials; individual results will vary. Week one contributes to that arc in the same way that day one of a consistent habit contributes to its long-term outcome: it matters, but the results belong to the full timeline.

A useful mindset for week one: pay attention to tolerability, establish the injection routine, drink enough water, and make the small food adjustments that prevent unnecessary nausea. The body is beginning to adapt to a medication that works cumulatively. Most of the first-week discomfort, if any, resolves before the second dose is due. Each successive week and each dose step typically brings clearer effects as the blood level rises and the body learns the new signals.

For a detailed look at what changes across the first three months, including what to expect during each dose increase and when weight loss typically becomes noticeable, see What should you expect in your first 90 days on a GLP-1? For a focused look at result timing, How fast does semaglutide work? covers the clinical evidence on early versus later effects in detail.